ideasIdea
Off-the-shelf KRAS vaccines after pancreatic cancer surgery
Almost every pancreatic cancer shares one of a handful of KRAS mutations. A pre-made vaccine against them could be given to every patient after surgery.
ELI-002 7P (Elicio) induced KRAS-specific T cells in >80% of patients with ctDNA correlations in phase 1; AMPLIFY-7P phase 2 randomised. Personalised vaccines (autogene cevumeran) work but take weeks and cost more.
Confidence
15%–35%likelyOnCo editors (initial estimate), 2026-09-07 · AMPLIFY-7P missed its primary endpoint in June 2026; immunogenicity is real, efficacy unproven.
Hypothesis
Adjuvant KRAS peptide/mRNA vaccination reduces recurrence in resected PDAC with MRD-positive disease, with T-cell response magnitude predicting benefit.
Rationale
Shared neoantigen, low tumour burden post-surgery, ctDNA to enrich and monitor; complements RAS inhibitors that may increase antigen presentation.
What would test it
Run a phase 2/3 with ctDNA-positive enrichment and an RFS endpoint; explore combination with daraxonrasib.
Maturity
early clinical